Literature review and meta-analysis of risk factors for delayed post-traumatic stress disorder in older adults after a fall

2016 ◽  
Vol 32 (2) ◽  
pp. 136-140 ◽  
Author(s):  
Frédéric Bloch
2015 ◽  
Vol 21 ◽  
pp. 17-24 ◽  
Author(s):  
Morten Birkeland Nielsen ◽  
Tone Tangen ◽  
Thormod Idsoe ◽  
Stig Berge Matthiesen ◽  
Nils Magerøy

2012 ◽  
Vol 32 (2) ◽  
pp. 122-138 ◽  
Author(s):  
David Trickey ◽  
Andy P. Siddaway ◽  
Richard Meiser-Stedman ◽  
Lucy Serpell ◽  
Andy P. Field

2015 ◽  
Vol 206 (2) ◽  
pp. 93-100 ◽  
Author(s):  
Mathew Hoskins ◽  
Jennifer Pearce ◽  
Andrew Bethell ◽  
Liliya Dankova ◽  
Corrado Barbui ◽  
...  

BackgroundPharmacological treatment is widely used for post-traumatic stress disorder (PTSD) despite questions over its efficacy.AimsTo determine the efficacy of all types of pharmacotherapy, as monotherapy, in reducing symptoms of PTSD, and to assess acceptability.MethodA systematic review and meta-analysis of randomised controlled trials was undertaken; 51 studies were included.ResultsSelective serotonin reuptake inhibitors were found to be statistically superior to placebo in reduction of PTSD symptoms but the effect size was small (standardised mean difference −0.23, 95% CI −0.33 to −0.12). For individual pharmacological agents compared with placebo in two or more trials, we found small statistically significant evidence of efficacy for fluoxetine, paroxetine and venlafaxine.ConclusionsSome drugs have a small positive impact on PTSD symptoms and are acceptable. Fluoxetine, paroxetine and venlafaxine may be considered as potential treatments for the disorder. For most drugs there is inadequate evidence regarding efficacy for PTSD, pointing to the need for more research in this area.


Author(s):  
Juan Manuel Millan-Alanis ◽  
Farid Carranza-Navarro ◽  
Humberto de León-Gutiérrez ◽  
Paloma C. Leyva-Camacho ◽  
Andrea Fernanda Guerrero-Medrano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document